Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2025-02-14 00:00:00 ET · period of report 2025-02-12 · accession 0000914475-25-000055 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-02-14 | 2025-02-13 | NBIX | ABERNETHY MATT | CFO | M - OptEx | $0.00 | +4,807 | 37.0K | +15% | $0 |
| DM | 2025-02-14 | 2025-02-13 | NBIX | ABERNETHY MATT | CFO | S - Sale+OE | $116.86 | -2,558 | 35.8K | -7% | -$298.9K |
| DM | 2025-02-14 | 2025-02-13 | NBIX | ABERNETHY MATT | CFO | M - OptEx | $0.00 | -4,807 | 6,725 | -42% | $0 |
| DM | 2025-02-14 | 2025-02-12 | NBIX | ABERNETHY MATT | CFO | A - Grant | $0.00 | +54.1K | 45.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-13 | M | A | 2,566 | $0.00 | 36,127 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-13 | S | D | 1,352 | $116.85 | 34,775 | D | — | — | (F2) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.02 to $118.29. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 3 | Common | Common Stock | 2025-02-13 | M | A | 2,241 | $0.00 | 37,016 | D | — | — | |
| 4 | Common | Common Stock | 2025-02-13 | S | D | 1,206 | $116.87 | 35,810 | D | — | — | (F4) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.02 to $117.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 5 | Derivative | Restricted Stock Unit | 2025-02-13 | M | D | 2,566 | $0.00 | 5,132 | D | — · — to — | 2,566 Common Stock | (F6) Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. (F8) This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,566 shares on February 13, 2024, vested as to 2,566 shares on February 13, 2025, and will vest as to 2,566 shares on February 13, 2026, and 2,566 shares on February 13, 2027, subject to the terms and conditions of the award. |
| 6 | Derivative | Restricted Stock Unit | 2025-02-12 | A | A | 8,534 | $0.00 | 8,534 | D | — · — to — | 8,534 Common Stock | (F6) Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. (F7) The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029. |
| 7 | Derivative | Stock Option | 2025-02-12 | A | A | 45,538 | $0.00 | 45,538 | D | $117.18 · — to 2035-02-12 | 45,538 Common Stock | (F5) Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. |
| 8 | Derivative | Restricted Stock Unit | 2025-02-13 | M | D | 2,241 | $0.00 | 6,725 | D | — · — to — | 2,241 Common Stock | (F6) Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. (F9) This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,241 shares on February 13, 2025, and will vest as to 2,241 shares on February 13, 2026, 2,242 shares on February 13, 2027, and 2,242 shares on February 13, 2028, subject to the terms and conditions of the award. |